A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...

Exelixis (EXEL) stock surged 7.3% after winning a patent battle against generic drug maker MSN Laboratories over Cabometyx.

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.

The Delaware District Court ruled in EXEL's favor, rejecting MSN's challenge to three patents related to cabozantinib.

Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.

In addition to the legal success, Exelixis has received an upgrade from B of A Securities. The firm has maintained a Buy rating and raised the price target from $30 to $32. This optimistic outlook ...

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday after Bank of America raised their price target on the stock from $30.00 to ...

Probably best known for the cancer drug Cabometyx (cabozantinib), which is marketed by Ipsen outside of the US and Japan, Exelixis already has four small-molecule drugs on the market. But CEO ...

Indian benchmark indices Nifty 50 and Sensex ended lower in the previous trade session. Nifty 50 closed at 25,057.35, while Sensex ended at 81,820.12. Overnight, Wall Street indices tumbled from ...

India on Thursday weighed in on the ongoing diplomatic spat with Canada by holding the Trudeau administration responsible for 'precipitating' the current diplomatic fallout while acknowledging the ...